Immatics looks to build on momentum for TCR T cell therapy 

Immatics believes a durable 50-80% objective response rate for IMA203 at six months would make the PRAME-targeting engineered TCR cell therapy “medically meaningful” and “commercially viable,” CMO Cedrik Britten said Monday.

The comments came on a conference call with investors after  Immatics N.V. (NASDAQ:IMTX) reported that IMA203 showed promising efficacy results in multiple PRAME-positive solid tumors in a Phase I study. At week 12, 50% (6/12) of patients had a confirmed objective response, and four of five patients in the Phase Ib portion of the trial achieved an ORR, as of Sept. 6 data cut-off. ...